Geron Corporation

NASDAQ:GERN

Biotechnology

Healthcare
$0.99 +4.07%

+$0.05 today

Market cap
$638.38M
Beta
0.60
P/E (TTM)
-12.3
EPS (TTM)
-$0.10
52W Low $1.04High $2.01

Volume 34.97M

Average 16.28M

GERN Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Geron CorporationNASDAQ: GERN

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development declines year over year

Q1 FY2026 research & development of $14.96M fell 0.8% year over year, ahead of the -17.7% change in trailing-twelve-month research & development. Sequentially, it fell 5.5% from the prior quarter. Over 3 fiscal years it compounded at -8.3% a year.

Context

  • Research & development amounted to 40.1% of revenue in FY2025, down 94.6 pp from a year earlier.
  • Research & development increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of -0.8% holds above the trailing-twelve-month pace of -17.7%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$14.96M-5.5% QoQ
Last fiscal yearDec 2025
$73.72M-28.9% YoY
LTMMar 2026
$73.59M-17.7% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-0.8%——
1 year-28.9%——
3-year CAGR-8.3%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
73.72M USD
Year-over-year change
-28.9%
4-year CAGR
-3.7%

Research & Development vs competitors

How GERN compares with its peers on the latest reported figures

  • GERN's LTM Mar 2026 research & development of $73.59M is the 4th highest of the 8 companies compared; the peer median is $59.63M.
  • Its year-over-year change of -17.7% is the 5th highest of 7, against a peer median of +25.4%.
  • Research & development amounts to 37.5% of revenue for GERN, versus a peer median of 37.0%.
GERN Competitors Peer median
Research & Development for GERN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
INCYIncyte CorporationLTM Jun 2026$2.15B +9.1%+8.9%37.0%
DMRADamora Therapeutics, Inc.LTM Mar 2026$224.29M +4762.0%+61.0%—
IPSCCentury Therapeutics, Inc.LTM Mar 2026$83.18M -24.7%-0.5%—
GERNGeron CorporationLTM Mar 2026$73.59M -17.7%-8.3%37.5%
COAGHemab Therapeutics Holdings, Inc. Common StockFY2025$59.63M ———
RIGLRigel Pharmaceuticals, Inc.LTM Mar 2026$36.54M +41.7%-17.9%12.2%
SLSSELLAS Life Sciences Group, Inc.LTM Sep 2026$23.16M +47.2%-19.1%—
ATNMActinium Pharmaceuticals, Inc.LTM Jun 2026$18.74M -30.0%-3.0%53.4%
Peer median (excluding GERN) $59.63M+25.4%-1.8%37.0%

Competitors are the stored peer set for GERN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue1.39M596K237K76.99M183.88M
Cost of Revenue0001.26M4.75M
Gross Profit1.39M596K237K75.74M179.14M
Gross Margin100.0%100.0%100.0%98.4%97.4%
Research & Development85.73M95.52M125.05M103.74M73.72M
Selling, General & Admin29.67M43.63M69.14M145.73M159.26M
Operating Expenses115.39M139.15M194.18M249.47M232.97M
Depreciation & Amortization783K868K1.03M1.22M1.2M
EBITDA(111.59M)(134.15M)(174.78M)(154.85M)(51.92M)
EBITDA Margin-8010.7%-22508.6%-73747.7%-201.1%-28.2%
Operating Income(114M)(138.55M)(193.94M)(173.73M)(53.84M)
Operating Margin-8183.7%-23246.6%-81832.9%-225.6%-29.3%
Interest Income527K2.53M18.15M19.61M18.12M
Interest Expense3.74M6.88M8.31M18.5M32.66M
Other Income / Expenses(2.11M)(3.35M)9.82M(840K)(31.95M)
Income Before Tax(116.11M)(141.9M)(184.13M)(174.57M)(85.78M)
Pre-Tax Margin-8335.4%-23808.9%-77690.7%-226.7%-46.7%
Income Tax Expense00000
Net Income(116.11M)(141.9M)(184.13M)(174.57M)(85.78M)
Net Margin-8335.4%-23808.9%-77690.7%-226.7%-46.7%
EPS (Basic)(0.37)(0.37)(0.32)(0.27)(0.13)
EPS (Diluted)(0.37)(0.37)(0.32)(0.27)(0.13)
Weighted Avg Shares327.63M380.78M570.65M646.03M666.66M
Weighted Avg Shares (Diluted)327.63M380.78M570.65M646.03M666.66M

Geron Corporation

NASDAQ:GERN

Intrinsic Alpha fair value

Locked

Current Price

$0.99

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.